Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Base Pair Biotechnologies Completes $3.2 Million Series A-3 Financing Round and Opens New Facility

Base Pair Biotechnologies,Inc.
Posted on: 28 Nov 17

Base Pair Biotechnologies, Inc., The Aptamer Discovery Company™, today announced the completion of its $3.2 Million Series A-3 financing round and the opening of its new 5,000 square foot laboratory and office facility in Pearland, TX, a Houston suburb. Toronto-based Eventi Capital Partners Inc. and Base Pair Canada led the round, with participation from earlier investors Houston-based BioTex, Inc. and Ashok Gowda, BioTex’s President & CEO, one of Base Pair’s founders.

Base Pair combines a highly customized aptamer discovery approach with a patented multiplexing technology, bringing together DNA barcoding and next generation sequencing to enable simultaneous identification of aptamers that bind up to 30 different targets. Aptamers are small, synthetic RNA or DNA molecules that fold into unique shapes, which enable them to selectively and tightly bind to molecular, viral or cellular targets. Base Pair will use the investment to acquire new lab instruments and other technology that will allow the company to expand its cellular and molecular analysis capabilities, enabling improved methods for finding aptamers that bind targets on and in live cells. The funding will also be used to expand the team, providing additional technical capability and enhancing geographical reach.

“Aptamers provide solutions to customer problems that are hard, if not impossible to solve with antibodies,” said Vicki Singer, President and CEO of Base Pair, “especially for small molecule targets, toxic molecules, and targets with low antigenicity. Base Pair’s unique value proposition lies in the scientific strength and creativity of its team, which includes cell biologists, molecular and microbiologists and biochemists, with decades of experience.”

“The focus on problem-solving rather than aptamer generation really sets Base Pair apart,” said Scott Bryan, Managing Partner, Eventi. “We believe that the company is poised to rapidly expand in multiple market sectors and are pleased to have the opportunity to participate.” Eventi is a growth capital investment group founded in 2001, specializing in software-as-a-service, internet infrastructure services, medical devices and life sciences.

“Base Pair is delivering great results with tremendous growth potential that we’re excited to continue to support,” said Michele Gowda of Base Pair Canada.

About Base Pair Biotechnologies

Base Pair Biotechnologies is a privately held aptamer discovery and development company, spun out of Biotex, Inc. in 2012. The company provides custom aptamer discovery and development services, as well as offering a small line of catalog aptamers, and has a significant and growing intellectual property portfolio in the aptamer space. Base Pair serves a diverse range of customer segments, including pharma and biopharma, diagnostics, environmental testing, and veterinary medicine.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171128005399/en/

Business Wire
www.businesswire.com

Last updated on: 28/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.